Beckman Coulter Life Sciences, a global leader in laboratory  automation and innovation, continues its mission to reduce workflow times and grueling manual steps  with the launch of its new Valita Aggregation Pure assay. The plate-based 96-well screening tool offers  rapid, high-throughput protein aggregation detection and quantification, providing robust aggregation data  in as little as 15 minutes. 

Traditional workflows in monoclonal antibody production require long wait times of up to six hours to  determine protein aggregation levels. The new Valita Aggregation Pure assay from Beckman Coulter Life  Sciences cuts through the clutter, delivering a rapid solution that is among the fastest and simplest  aggregation detection tools on the market, and is compatible with high-performance microplate readers  with fluorescence polarization functionality. 

“Processing thousands of samples to generate a commercially viable cell line is a complex and tedious  process that can slow laboratory workflows,” said Dr. Elisa Nent, Global Product Manager - Cell Health. “We continue to hear the critical need to rapidly measure antibody aggregation faster than traditional  DLS/SLS and HPLC-SEC methods. Our innovation slashes manual steps, the need for additional  reagents, and added expense – all in a fraction of the time. We’re confident this will allow laboratory staff  to get results faster and focus their efforts on critical research goals.” 

The new assay enhances the process development workflow by enabling detection and quantification of  antibody aggregation at any stage of time. In less than 15 minutes, aggregation can be quantified by  simply adding purified samples to the plate, incubating at room temperature, and measuring aggregation  using a plate reader. Available as 96-well plates and validated with samples concentrated between 200- 2,000 milligrams per liter, with a detection limit of 0.5% aggregation at 1,000 milligrams per liter, it enables  rapid, high-throughput protein aggregation analysis.